1353995-46-6

Basic information

• Product Name: (R)-1-(2,4-Dichloro-benzenesulfonyl)-pyrrolidin-3-ol
• Synonyms: (R)-1-(2,4-Dichloro-benzenesulfonyl)-pyrrolidin-3-ol;(R)-1-((2,4-Dichlorophenyl)sulfonyl)pyrrolidin-3-ol
• CAS NO: 1353995-46-6
• Molecular Formula: C10H11Cl2NO3S
• Molecular Weight: 296.17024
• Mol File: 1353995-46-6.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 451.4±55.0 °C(Predicted)
• Appearance: /
• Density: 1.575±0.06 g/cm3(Predicted)
• PKA: 14.21±0.20(Predicted)
• CAS DataBase Reference: (R)-1-(2,4-Dichloro-benzenesulfonyl)-pyrrolidin-3-ol(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-1-(2,4-Dichloro-benzenesulfonyl)-pyrrolidin-3-ol(1353995-46-6)
• EPA Substance Registry System: (R)-1-(2,4-Dichloro-benzenesulfonyl)-pyrrolidin-3-ol(1353995-46-6)

Safety Data

• Hazardous Substances Data: 1353995-46-6(Hazardous Substances Data)

Usage

General Description

The chemical (R)-1-(2,4-dichloro-benzenesulfonyl)-pyrrolidin-3-ol is a compound with the molecular formula C10H10Cl2NO3S. It is a pyrrolidinol derivative with a 2,4-dichloro-benzenesulfonyl group attached to the pyrrolidin-3-ol moiety. (R)-1-(2,4-Dichloro-benzenesulfonyl)-pyrrolidin-3-ol has potential pharmaceutical and biological applications, particularly as a building block in the synthesis of other organic molecules and as a potential drug candidate. Its chemical structure suggests that it may have interactions with various biological targets, although its specific pharmacological activities are not fully characterized. The compound's properties and potential applications make it an interesting molecule for further research and development in the fields of medicinal and organic chemistry.

Upstream product

• 40499-83-0 pyrrolidin-3-ol 
• 16271-33-3 2,4-Dichlorobenzenesulfonyl chloride 

Relevant articles and documents

Discovery of Pyrrolidine Sulfonamides as Selective and Orally Bioavailable Antagonists of Transient Receptor Potential Vanilloid-4 (TRPV4)

A novel series of pyrrolidine sulfonamide transient receptor potential vanilloid-4 (TRPV4) antagonists was developed by modification of a previously reported TRPV4 inhibitor (1). Several core-structure modifications were identified that improved TRPV4 activity by increasing structural rigidity and reducing the entropic energy penalty upon binding to the target protein. The new template was initially discovered as a minor regio-isomeric side product formed during routine structure-activity relationship (SAR) studies, and further optimization resulted in highly potent compounds with a novel pyrrolidine diol core. Further improvements in potency and pharmacokinetic properties were achieved through SAR studies on the sulfonamide substituent to give an optimized lead compound GSK3395879 (52) that demonstrated the ability to inhibit TRPV4-mediated pulmonary edema in an in vivo rat model. GSK3395879 is a tool for studying the biology of TRPV4 and an advanced lead for identifying new heart failure medicines.